<DOC>
	<DOCNO>NCT02399462</DOCNO>
	<brief_summary>This open label safety feasibility trial use Acthar® addition center-specific standard therapy include plasma exchange , treatment post transplant recurrent FSGS post transplant recurrent idiopathic membranous nephropathy . Subjects receive Acthar® 40 unit subcutaneously twice weekly two week 80 unit subcutaneously twice weekly 24 week .</brief_summary>
	<brief_title>Acthar Treatment Post-transplant FSGS</brief_title>
	<detailed_description />
	<mesh_term>Adrenocorticotropic Hormone</mesh_term>
	<mesh_term>Melanocyte-Stimulating Hormones</mesh_term>
	<mesh_term>beta-Endorphin</mesh_term>
	<criteria>Age &gt; 18 year Proteinuria &gt; 1 g/d urine protein/creatinine ratio ( UP/C ) 24 hour urine collection ( timepoint ? ) If treat angiotensinconvertingenzyme inhibitor ( ACEi ) Angiotensin II receptor blocker ( ARB ) , must stable dose least 2 week prior enrollment Newly diagnose recurrent focal segmental glomerulosclerosis ( FSGS ) , current/previous treatment recurrent FSGS evidence least partial response define one following : 1 . Recurrent FSGS confirm renal transplant biopsy ( FSGS light microscopy and/or foot process effacement electron microscopy ) , FSGS primary disease confirm native renal biopsy prior transplant 2 . FSGS confirm renal transplant biopsy ( FSGS light microscopy and/or foot process effacement electron microscopy ) , within 18 month post transplant 3 . Patients time period post transplant establish diagnosis recurrent FSGS first 18 month post transplant respond conventional therapy define persistent proteinuria &gt; 3 g/d UP/C 24 hour urine collection Lactation , pregnancy refusal birth control woman childbearing potential Infection human immunodeficiency virus ( HIV ) , hepatitis B , hepatitis C , parvovirus B19 Malignancy ( exception treat cure basal cell squamous cell carcinoma ) Evidence diabetic nephropathy , transplant glomerulopathy pathology could associate secondary FSGS renal transplant biopsy Nonrenal organ transplant ( exception pancreas transplant ) Contraindication receive Acthar®</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2016</verification_date>
</DOC>